BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34307165)

  • 41. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
    J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC).
    Oronsky B; Abrouk N; Caroen S; Lybeck M; Guo X; Wang X; Yu Z; Reid T
    J Cancer; 2022; 13(9):2945-2953. PubMed ID: 35912017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
    Tjan-Heijnen VC; Postmus PE; Ardizzoni A; Manegold CH; Burghouts J; van Meerbeeck J; Gans S; Mollers M; Buchholz E; Biesma B; Legrand C; Debruyne C; Giaccone G;
    Ann Oncol; 2001 Oct; 12(10):1359-68. PubMed ID: 11762805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
    Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B
    Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor.
    Bartucci M; Dattilo R; Martinetti D; Todaro M; Zapparelli G; Di Virgilio A; Biffoni M; De Maria R; Zeuner A
    Clin Cancer Res; 2011 Oct; 17(19):6185-91. PubMed ID: 21868766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors.
    Smith RE
    J Natl Compr Canc Netw; 2006 Aug; 4(7):649-58. PubMed ID: 16884668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
    D'Hondt V; Weynants P; Humblet Y; Guillaume T; Canon JL; Beauduin M; Duprez P; Longueville J; Müll R; Chatelain C
    J Clin Oncol; 1993 Nov; 11(11):2063-71. PubMed ID: 8229120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
    Yashiki C; Hirose T; Sugiyama T; Kusumoto S; Shirai T; Ohmori T; Adachi M; Nakamura A
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):245-9. PubMed ID: 20154478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
    de Sousa MJ; Gervaso L; Meneses-Medina MI; Spada F; Abdel-Rahman O; Fazio N
    Curr Oncol Rep; 2022 Jun; 24(6):715-722. PubMed ID: 35262877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.
    Bokemeyer C; Kuczyk MA; Köhne H; Einsele H; Kynast B; Schmoll HJ
    Ann Hematol; 1996 Jan; 72(1):1-9. PubMed ID: 8605273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.